Mucin 2 (MUC2) modulates the aggressiveness of breast cancer
- 138 Downloads
Tumors that secrete large volumes of mucus are chemotherapy resistant, however, mechanisms underlying this resistance are unknown. One protein highly expressed in mucin secreting breast cancers is the secreted mucin, Mucin 2 (MUC2). While MUC2 is expressed in some breast cancers it is absent in normal breast tissue, implicating it in breast cancer. However, the effects of MUC2 on breast cancer are largely unknown. This study examined the role of MUC2 in modulating breast cancer proliferation, response to chemotherapy and metastasis.
Using patient derived xenografts we developed two novel cell lines, called BCK4 and PT12, which express high levels of MUC2. To modulate MUC2 levels, BCK4 and PT12 cells were engineered to express shRNA targeted to MUC2 (shMUC2, low MUC2) or a non-targeting control (shCONT, high MUC2) and proliferation and apoptosis were measured in vitro and in vivo. BCK4 cells with shCONT or shMUC2 were labeled with GFP-luciferase and examined in an experimental metastasis model; disease burden and site specific dissemination were monitored by intravital imaging and fluorescence guided dissection, respectively.
Proliferation decreased in BCK4 and PT12 shMUC2 cells versus control cells both in vitro and in vivo. Chemotherapy induced minimal apoptosis in control cells expressing high MUC2 but increased apoptosis in shMUC2 cells containing low MUC2. An experimental metastasis model showed disease burden decreased when breast cancer cells contained low versus high MUC2. Treatment with Epidermal Growth Factor (EGF) increased MUC2 expression in BCK4 cells; this induction was abolished by the EGF-receptor inhibitor, Erlotinib.
MUC2 plays an important role in mediating proliferation, apoptosis and metastasis of breast cancer cells. MUC2 may be important in guiding treatment and predicting outcomes in breast cancer patients.
KeywordsBreast cancer Mucin 2 Metastasis Mucinous Estrogen receptor
We thank Dr. Carol Sartorius for helpful comments on the manuscript. We also thank the following University of Colorado Cancer Center Core laboratories: Tissue Culture Core, Functional Genomics Facility, the University of Colorado Cancer Center (P30CA046984), and the University of Colorado Anschutz Medical Campus Biorepository Core Facility.
This study was supported by the University of Colorado Cancer Center Core Laboratories (P30CA046984). Funding provided by the University of Colorado Department of Pathology and the Breast Cancer Research Foundation. Studies also supported (in part) by a research grant from the Cancer League of Colorado, Inc (to BMJ).
Compliance with ethical standards
Conflict of interest
Anna Astashchanka declares that she has no conflict of interest. Thomas M. Shroka declares that he has no conflict of interest. Britta M. Jacobsen declares that she has no conflict of interest.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.
- 4.Yang C, Murray JL, Ibrahim NK (2018) MUC1 and cancer immunotherapy, vol 1. Elsevier Inc., Amsterdam, pp 225–240Google Scholar
- 7.Do SI, Kim K, Kim DH, Chae SW, Park YL, Park CH, Sohn JH (2013) Associations between the expression of mucins (MUC1, MUC2, MUC5AC, and MUC6) and clinicopathologic parameters of human breast ductal carcinomas. J Breast Cancer 16(2):152–158. https://doi.org/10.4048/jbc.2013.16.2.152 PubMedPubMedCentralGoogle Scholar
- 9.Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO (2005) Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 18(10):1295–1304. https://doi.org/10.1038/modpathol.3800445 PubMedGoogle Scholar
- 13.Adsay NV, Merati K, Nassar H, Shia J, Sarkar F, Pierson CR, Cheng JD, Visscher DW, Hruban RH, Klimstra DS (2003) Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs: Coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas. Am J Surg Pathol 27(5):571–578PubMedGoogle Scholar
- 14.Patel DS, Khandeparkar SGS, Joshi AR, Kulkarni MM, Dhande B, Lengare P, Phegade LA, Narkhede K (2017) Immunohistochemical study of MUC1, MUC2 and MUC5AC expression in primary breast carcinoma. J Clin Diagn Res 11(4):EC30–EC34. https://doi.org/10.7860/JCDR/2017/26533.9707 PubMedPubMedCentralGoogle Scholar
- 17.Nagao T, Kinoshita T, Hojo T, Tsuda H, Tamura K, Fujiwara Y (2012) The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. Breast 21(3):289–295. https://doi.org/10.1016/j.breast.2011.12.011 PubMedGoogle Scholar
- 18.Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thurlimann B, Ejlertsen B, MacGrogan G, Bibeau F, Lelkaitis G, Price KN, Gelber RD, Coates AS, Goldhirsch A, Colleoni M, International Breast Cancer Study G, the BIGCG (2015) Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1–98 trial. Ann Oncol 26(12):2442–2449. https://doi.org/10.1093/annonc/mdv391 PubMedPubMedCentralGoogle Scholar
- 20.Siegelmann-Danieli N, Silverman B, Zick A, Beit-Or A, Katzir I, Porath A (2013) The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer: the Maccabi Healthcare Services experience with a unified testing policy. Ecancermedicalscience 7:380. https://doi.org/10.3332/ecancer.2013.380 PubMedPubMedCentralGoogle Scholar
- 21.Jambal P, Badtke MM, Harrell JC, Borges VF, Post MD, Sollender GE, Spillman MA, Horwitz KB, Jacobsen BM (2013) Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. Breast Cancer Res Treat 137(2):431–448. https://doi.org/10.1007/s10549-012-2377-x PubMedGoogle Scholar
- 22.Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA (2012) Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat 135(2):415–432. https://doi.org/10.1007/s10549-012-2164-8 PubMedGoogle Scholar
- 23.D’Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK (2016) Cooperative dynamics of AR and ER activity in breast cancer. Mol Cancer Res 14(11):1054–1067. https://doi.org/10.1158/1541-7786.MCR-16-0167 PubMedPubMedCentralGoogle Scholar
- 24.Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, Jordan VC, Bradford AP (2012) DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol 127(1):241–248. https://doi.org/10.1016/j.ygyno.2012.06.017 PubMedPubMedCentralGoogle Scholar
- 26.Badtke MM, Jambal P, Dye WW, Spillman MA, Post MD, Horwitz KB, Jacobsen BM (2012) Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint. Breast Cancer Res Treat 131(1):75–87. https://doi.org/10.1007/s10549-011-1399-0 PubMedGoogle Scholar
- 29.Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedren S, Bergh J (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7(6):R953–R964. https://doi.org/10.1186/bcr1325 PubMedPubMedCentralGoogle Scholar
- 34.Vokuda RS, Verma SK, Srinivas BH (2018) Tissue Microarray Technology-A Brief Review. Natl J Lab Med 7(1):PR01–PR04Google Scholar
- 35.Sonora C, Mazal D, Berois N, Buisine MP, Ubillos L, Varangot M, Barrios E, Carzoglio J, Aubert JP, Osinaga E (2006) Immunohistochemical analysis of MUC5B apomucin expression in breast cancer and non-malignant breast tissues. J Histochem Cytochem 54(3):289–299. https://doi.org/10.1369/jhc.5A6763.2005 PubMedGoogle Scholar
- 39.Garcia EP, Tiscornia I, Libisch G, Trajtenberg F, Bollati-Fogolin M, Rodriguez E, Noya V, Chiale C, Brossard N, Robello C, Santinaque F, Folle G, Osinaga E, Freire T (2016) MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells. Int J Oncol 48(5):2113–2123. https://doi.org/10.3892/ijo.2016.3434 PubMedGoogle Scholar
- 42.He YF, Zhang MY, Wu X, Sun XJ, Xu T, He QZ, Di W (2013) High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time. PLoS ONE 8(12):e79769. https://doi.org/10.1371/journal.pone.0079769 PubMedPubMedCentralGoogle Scholar
- 45.Scully OJ, Bay BH, Yip G, Yu Y (2012) Breast cancer metastasis. Cancer Genom Proteom 9(5):311–320Google Scholar
- 50.Leteurtre E, Gouyer V, Rousseau K, Moreau O, Barbat A, Swallow D, Huet G, Lesuffleur T (2004) Differential mucin expression in colon carcinoma HT-29 clones with variable resistance to 5-fluorouracil and methotrexate. Biol Cell 96(2):145–151. https://doi.org/10.1016/j.biolcel.2003.12.005 PubMedGoogle Scholar